News

Labcorp Holdings, Inc. LH has announced the nationwide availability of the Lumipulse pTau-217/Beta Amyloid 42 Ratio — the first FDA-cleared blood-based in-vitro diagnostic (IVD) test to assist in ...
Labcorp (LH) announced the availability of the Lumipulse pTau-217/Beta Amyloid 42 Ratio, the first blood-based in-vitro diagnostic test cleared by ...
Labcorp introduces US FDA approved blood test, Lumipulse pTau-217/Beta Amyloid 42 Ratio for Alzheimer's disease: Burlington, North Carolina Tuesday, August 19, 2025, 14:00 Hrs [IS ...
Labcorp Holdings (LH) experienced a 10% price increase in the past month, which aligns with its recent strategic advancements including the launch of Lumipulse® pTau-217/Beta Amyloid 42 Ratio, marking ...
Seniors experiencing memory problems and cognitive decline now have access to a new diagnostic blood test to detect Alzheimer’s disease. Labcorp this week unveiled the first Food and Drug ...
The FDA has cleared Lumipulse, the first-ever blood test for early Alzheimer's detection, reducing the need for costly and invasive procedures.
The US Food and Drug Administration (FDA) has granted 510(k) clearance to the first blood test to aid in diagnosing Alzheimer’s disease (AD). The Lumipulse G pTau217/Beta-Amyloid 1-42 Plasma ...
The Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio test is designed for the early detection of amyloid plaques associated with Alzheimer’s disease in adults aged 55 years and older who are ...
The Lumipulse blood test is made by Japanese company, Fujirebio Diagnostics, which markets a similar Alzheimer's test that measures cerebrospinal fluid collected by spinal tap. The company did not ...
Fujirebio Expands Its Alzheimer’s Disease Test Menu With the Much Awaited and Fully Automated Lumipulse® G pTau 217 Plasma Assay for Research Use Only (RUO) December 22, 2023 12:23 PM Eastern ...
Labcorp has launched the first blood-based in-vitro diagnostic test cleared by the Food and Drug Administration to aid in the diagnosis of Alzheimer's disease.
The Lumipulse blood test is made by Japanese company, Fujirebio Diagnostics, which markets a similar Alzheimer's test that measures cerebrospinal fluid collected by spinal tap.